Over recent weeks I have been intrigued to hear some highly negative comments from people outside of the biopharm community on the industries economic value and also concerns regarding the public perception of the potential use of live recombinant products being a reason not to progress along this track. Over the last 30 years, the industry has grown from what was in many cases nothing more than a scientific novelty, into multi-billion dollar products. This has been achieved in the face...
